Omeros (OMER)
(Delayed Data from NSDQ)
$3.36 USD
+0.04 (1.20%)
Updated May 31, 2024 04:00 PM ET
After-Market: $3.36 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Brokerage Reports
Omeros Corporation [OMER]
Reports for Purchase
Showing records 201 - 220 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Q2:15 Update; Omidria Launch Off to a Good Start, in Our View; Reiterate OUTPERFORM and $61 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
We are initiating coverage of Omeros Corporation with a Buy rating and 12- month target price of $38/share.
Provider: Roth Capital Partners, Inc.
Analyst: PIERCE E
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Omeros Corporation
Industry: Medical - Products
Omeros Announced EU Approval of Omidria; Reiterate OUTPERFORM and $61 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
August and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Fast Track Designation for OMS721 Treatment of aHUS Reduces Regulatory Risk, in Our View; Reiterate OUTPERFORM and $61 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Recent Weakness is a Buying Opportunity for Potential 2015 Catalysts in Our View; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
July and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Enters into Exclusive Licensing Agreement for OMS103; Reiterate OUTPERFORM and $61 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Emerging Pharmaceuticals - June and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Unanimously Positive CHMP Recommendation Suggests EU Approval in July and Partnership in H2 in Our View; Reiterate OUTPERFORM and $61 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q1 Financials Beat; OMIDRIA US Launch Underway and Pipeline Progress Continues; Reiterate OUTPERFORM and $61 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
May and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
May and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Compassionate Use in aHUS Patients Approved for OMS721 in Europe and Second Phase 2 Cohort Completes Treatment; Reiterate OUTPERFORM and $61 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Compassionate Use in aHUS Patients Approved for OMS721 in Europe and Second Phase 2 Cohort Completes Treatment; Reiterate OUTPERFORM and $61 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
We Believe Groundwork Laid for a Successful US Launch of OMIDRIA. Reiterate OUTPERFORM and Raising PT to $61 for US Launch.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 6th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
April and 2015 Emerging Pharmaceuticals CatalystsThis report contains brief updates on the following: BIOD, BMRN, ICPT, LXRX, OMER, RCPT, RLYP, SGMO, VTAE, XOMA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L